STOPPFrail 标准用于临终老年人的减药随机对照试验
本研究在爱尔兰两家急性医院纳入130例75岁以上、晚期衰弱且多重用药(≥5种药物)、正转入长期护理机构的老年人,随机分为STOPPFrail引导减药组与对照组。结果显示干预组3个月时常规用药数量与月度药费显著下降,但跌倒、非计划入院、生活质量与死亡率组间无显著差异,且试验对这些次要结局可能检验效能不足。
要点
- STOPPFrail引导减药可显著减少晚期衰弱老年人的常规用药数量。
- 干预组月度药费下降幅度显著大于对照组。
- 跌倒、非计划入院、生活质量与死亡率未见显著组间差异。
核心结论
- STOPPFrail引导的减药可显著减少晚期衰弱老年人的多重用药和药物费用。
- 跌倒、入院、生活质量和死亡率方面未观察到显著组间差异,但试验对这些结局可能检验效能不足。
研究设计与样本
- 随机对照试验,在爱尔兰两家急性医院开展。
- 纳入130例75岁及以上、晚期衰弱且多重用药(≥5种药物)、正转入长期护理机构的成年人。
- 干预为将STOPPFrail引导的减药方案提交给主治医师,由其判断是否实施推荐药物调整。
主要发现
- 干预组(n=65)与对照组(n=65)基线平均用药数分别为11.5(±3.0)和10.9(±3.5)种。
- 其他次要结局(非计划入院、跌倒、生活质量、死亡率)组间均无显著差异。
关键数值与推荐
- 研究对象为75岁及以上、晚期衰弱且使用≥5种药物、正转入长期护理机构者。
- 主要结局为3个月时常规用药数量的变化。
- STOPPFrail减药方案由主治医师判断是否实施。
临床怎么用
- 对晚期衰弱、多重用药且转入长期护理机构的老年人,可考虑采用STOPPFrail引导减药以降低用药负担和药费。
- 减药决策由主治医师结合患者具体情况判断是否实施推荐调整。
- 实施减药时需关注跌倒、非计划入院、生活质量和死亡率等结局,但本试验对这些结局的检验效能可能不足。
局限性
- 试验对跌倒、入院、生活质量和死亡率等次要结局可能检验效能不足。
- 研究在爱尔兰两家急性医院开展,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Older people approaching end of life are commonly prescribed multiple medications, many of which may be inappropriate or futile. Our objective was to examine the effect of applying the STOPPFrail, a recently developed deprescribing tool, to the medication regimens of older patients with advanced frailty. DESIGN: Randomized controlled trial. SETTING: Two acute hospitals in Ireland. PARTICIPANTS: Adults 75 years or older (n = 130) with advanced frailty and polypharmacy (five or more drugs), transferring to long-term nursing home care. INTERVENTION: A STOPPFrail-guided deprescribing plan was presented to attending physicians who judged whether or not to implement recommended medication changes. MEASUREMENTS: The primary outcome was the change in the number of regular medications at 3 months. Secondary outcomes included unscheduled hospital presentations, falls, quality of life, monthly medication costs, and mortality. RESULTS: Intervention (n = 65) and control group (n = 65) participants were prescribed a mean (plus or minus standard deviation [SD]) of 11.5 (±3.0) and 10.9 (±3.5) medications, respectively, at baseline. The mean (SD) change in the number of medications at 3 months was -2.6 (±2.73) in the intervention group and -.36 (±2.60) in the control group (mean difference = 2.25 ± .54; 95% confidence interval [CI] = 1.18-3.32; P < .001). The mean change in monthly medication cost was -$74.97 (±$148.32) in the intervention group and -$13.22 (±$110.40) in the control group (mean difference $61.74 ± $26.60; 95% CI = 8.95-114.53; P = .02). No significant differences were found between groups for any of the other secondary outcomes. CONCLUSION: STOPPFrail-guided deprescribing significantly reduced polypharmacy and medication costs in frail older people. No significant differences between groups were observed with regard to falls, hospital presentations, quality of life, and mortality, although the trial was likely underpowered to detect differences in these outcomes. J Am Geriatr Soc 68:762-769, 2020.
引用
- Curtin D, Jennings E, Daunt R, et al. Deprescribing in Older People Approaching End of Life: A Randomized Controlled Trial Using STOPPFrail Criteria. J Am Geriatr Soc. 2019. PMID: 31868920. doi:10.1111/jgs.16278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。